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Abstract
Background:  Familial keloids have been reported, having either autosomal dominant or
autosomal recessive inheritance. We wished to determine the inheritance pattern and phenotype
of keloids among multigenerational families, as a prelude to a positional mapping strategy to identify
candidate genes.
Methods: We studied three African American families, one Afro-Caribbean family and one Asian-
American family. Phenotyping including assessing all patients for the presence, distribution, and
appearance of keloids, together with the timing of keloid onset and provocative factors. The clinical
trial was registered at clinicaltrials.gov (NCT 00005802).
Results: Age of keloid onset varied considerably within families, but commonly occurred by the
second decade. The fraction of affected individuals was 38%, 45%, 62%, 67% and 73% among the
five families respectively. Keloid severity and morphology differed within and between families. A
novel finding is that certain families manifest keloids in distinct locations, with one family showing
an excess of extremity keloids and two families showing an excess of axilla-groin keloids.
Conclusion:  Familial keloids appear to most commonly manifest autosomal dominant or
semidominant inheritance, and there may be familial patterns of keloid distribution.
Background
Keloids represent an exuberant wound healing response
that may occur spontaneously or following cutaneous
injury. Worldwide keloid prevalence varies by geographic
ancestry from 0.09% in Great Britain to 16% in the Congo
[1]. Although keloid prevalence in United States is not
well documented, darker-skinned individuals and those
of African descent seem to be disproportionately affected
[2]. Keloid scars can impair physical and psychological
quality of life [3]. Available therapies have low efficacy
and/or significant morbidity. The International Clinical
Recommendations on Scar Management list a variety of
therapeutic approaches including triamcinolone, surgery,
radiation, and combination therapy [4]. A recent prospec-
tive study found greater than 70% recurrence at a mean
follow up of 19 months for surgical excision followed by
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irradiation [5]. Surgical resection with concomitant triam-
cinolone injection, is followed by a recurrence rate of up
to 20% and the recurrent lesion is often worse than the
original lesion [6]. Other therapies including intralesional
5-fluorouracil, calcium channel blockers, bleomycin,
cyclosporine, topical retinoic acid and imiquimod have
shown some promise in the treatment of keloids, yet none
consistently outperform surgery with triamcinolone injec-
tion [6].
Keloids and hypertrophic scars are distinct clinically and
pathologically. Keloids may appear spontaneously or fol-
lowing trauma, expand beyond the margins of the wound,
and typically persist and expand for a number of years.
Hypertrophic scars occur following trauma, are limited to
the boundaries of the wound, and typically begin to
regress within one year of injury. Histologically, keloids
are characterized by a greatly expanded dermis occupied
by large, hyalinized collagen fibers that are strongly eosi-
nophilic, while hypertrophic scars are characterized by an
expanded dermis, with more numerous fibroblasts and
thin, newly deposited collagen fibers. Both keloids and
hypertrophic scars show dermal nodules comprised of
focal aggregates of fibroblasts together with randomly ori-
ented collagen fibers. In hypertrophic scars, the dermal
nodules have well-demarcated borders while in keloids
the borders are less distinct. In contrast to both keloids
and hypertrophic scars, normal scars lack dermal nodules,
contain loose aggregates of fibroblasts arranged in parallel
to the epidermis, and exhibit less conspicuous collagen
fibers. Ehrlich et al. demonstrated that alpha-smooth
muscle actin expressing myofibroblasts are specific to
hypertrophic scars and are absent from normal scars and
keloids [7]. Burd and Huang, however, highlight discrep-
ancies among histologic descriptions of keloids and
hypertrophic scars, concluding that histology changes
through time and may also vary within a scar at a single
time point [8].
Numerous theories have been proposed for the pathogen-
esis of keloids. [6] Recently the role of TGF-beta, a
cytokine important in wound healing and fibrosis, has
been explored in keloids. Cultured keloid fibroblasts
demonstrate increased fibroblast proliferation, TGF-beta
expression, and collagen production. Xia and colleagues
showed that TGF-beta2 production increases following
serum stimulation of keloid fibroblasts [9]. Moreover,
Sato demonstrated that keloid fibroblasts express more
beta-catenin, a TGF-beta downstream effector molecule
[10]. Further, expression of SMAD6 and SMAD7, which
terminate TGF-beta signaling, is downregulated in keloid
tissue. On the other hand, Bayat and colleagues found
that plasma TGF-beta1 levels did not vary significantly
between Caucasian patients with keloids, hypertrophic
scars and controls and that polymorphisms in TGFB1,
TGFB2, and TGFBR1 were not associated with keloids or
hypertrophic scars [11-13].
Three investigative groups, working with diverse racial
and ethnic populations, have concluded that familial kel-
oids manifest autosomal dominant inheritance. Bloom
reported 31 mostly European keloid pedigrees, including
one of African origin[14]; Marneros et al. reported 14
American keloid pedigrees [15]; and Chen et al. reported
6 Han Chinese pedigrees [16]. Omo-Dare, et al. however,
analyzed 34 pedigrees in Nigeria and concluded that the
data indicated recessive inheritance [17]. Recently, genetic
loci have been identified in two families with autosomal
dominant keloids, at 2q23 (Japanese family) and 7p11
(African-American family) [18]. Both loci were subse-
quently excluded in two Han Chinese families with kel-
oids; preliminary data from one of these families suggests
potential linkage at 10q23.31 [19].
Keloids have been reported in association with two
genetic syndromes. Rubinstein-Taybi syndrome manifests
beaked nose, widened terminal phalanges of the thumbs
and great toes, and mental retardation. In a review, Siraga-
nian et al. reported keloids in 28 of 574 cases [20]. The
syndrome has been linked to a variety of mutations at
16p13.3 (CBP), the gene that codes for the cAMP response
element binding (CREB) protein. CBP functions in multi-
ple signal transduction pathways and is thought to regu-
late the expression of many genes [21]. Goeminne
syndrome is characterized by torticollis, cryptorchidism,
renal dysplasia and multiple nevi. Three of the seven
reported cases had keloids. The syndrome has been asso-
ciated with balanced X/autosome translocation and
mapped to locus Xq28 [22].
We set out to further characterize the genetics of non-syn-
dromic familial keloids in the US population. We studied
five families each with three or more affected members
with at least two affected generations.
Methods
Subjects
The Institutional Review Board of the National Institute of
Diabetes, Digestive, and Kidney Diseases, National Insti-
tutes of Health (NIH) approved the research protocol,
which has been listed at http://www.ClinicalTrials.gov
since 2001. Investigators recruited patients from the der-
matology and plastic surgery departments of a nearby
teaching hospital. In addition, investigators sent letters
describing the study to local dermatologists and plastic
surgeons. Finally with IRB approval, NIH Patient Recruit-
ment Office placed advertisements in local newspapers.
Many subjects learned about the study either by calling
NIH to inquire about keloid studies or by finding the
research protocol on the Internet. Subjects with keloidsBMC Dermatology 2009, 9:8 http://www.biomedcentral.com/1471-5945/9/8
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contacted study investigators, and those with at least three
affected family members were asked to participate in fam-
ily studies. Subjects over 18 yrs of age gave informed con-
sent; subjects <18 yrs of age gave informed assent and
their parents or guardians gave informed consent to par-
ticipate in these studies. All probands resided within the
US. Using phone interviews, partial pedigrees were assem-
bled for 13 families, and five families were selected for fur-
ther study, based exclusively on the availability and
willingness of family members to participate. Geographic
ancestry (racial and ethnic background) was determined
by self-report.
For the five families presented here, detailed pedigrees
were constructed. Affected individuals who were deter-
mined by telephone interview to have keloids or possible
keloids were invited to travel to the NIH Clinical Center.
Nineteen of 35 affected subjects from the five families
were examined by a dermatologist (MT). An additional
seven affected subjects were examined in their home states
and photographs were taken for review by a dermatolo-
gist. No kindreds had evidence for Rubinstein-Taybi or
Goeminne syndromes on clinical exam. Ten affected sub-
jects were not available for examination. Of these, five
subjects were deceased, three subjects could not travel
(reasons included pregnancy, residence abroad and work
schedule), one subject refused, and one subject could not
be located by family members.
The clinical diagnosis of keloid was based on the follow-
ing criteria: a scar which extended beyond original wound
margins together with a history of continued scar growth
more than 12 months after appearance of the lesion.
Biopsy was not performed, due to risk of keloid exacerba-
tion. Hypertrophic scar was defined as a raised scar that
was confined to the boundaries of the original wound and
which reached maximum extent within 12 months of
onset, following by a period of slow regression. Photo-
graphs were taken of all keloids as well as many hyper-
trophic scars and normal scars.
The clinical ascertainment of unaffected family members
was generally made by self-identification, (individuals
stated that they had no unusual scars). Nine unaffected
subjects were examined at the NIH Clinical Center or in
their home state. When a subject was unsure as to whether
a scar was unusual and might represent a keloid, he or she
was examined at the NIH Clinical Center or in their home
state; five such patients were diagnosed with hypertrophic
scars. Blood was obtained from both affected and unaf-
fected subjects for a whole genome scan, which is under-
way at present.
Analysis of pedigrees
We prepared pedigrees for the five families (Figure 1). All
family members are shown in these pedigrees including 2
subjects whose clinical status is unknown and 23 children
<18 yrs old. We also prepared a tabulation of family mem-
bers with keloids, hypertrophic scars, and neither skin dis-
ease (Table 1). Keloids frequently appear for the first time
during adolescence and it is not possible to reliably deter-
mine keloid phenotype in children. Therefore, we
excluded all individuals <18 yrs from Table 1 as the inclu-
sion of these individuals would likely mis-categorize
some children as unaffected who will manifest keloids
later in life. In cases where individuals were deceased prior
to study onset, keloid status was assigned based on report
by family members. When possible, multiple family
members were contacted to confirm phenotype. When
family members did not know the phenotype of a
deceased relative, these individuals were characterized as
having unknown keloid status. The number of genera-
tions affected was determined based on the first genera-
tion manifesting keloids or an obligate carrier and the last
generation with at least one individual over 18 years of
age with or without keloids. Tabulations were calculated
across affected generations.
Analysis of keloid distribution and appearance
Information was recorded about each cutaneous lesion,
with particular emphasis on keloids and hypertrophic
scars; this included age of onset, inciting injury or event,
Table 1: Characteristics of five families with familial keloids
Family Ethnicity Generations studied Subjects Affected subjects 
(keloids)
Unaffected subjects 
(with hypertrophic 
scars)
Unaffected Subjects 
(no abnormal scars)
Unknown status
F African American 4 15 9 2 3 1
K African American 3 12 8 0 4 0
R African American 3 4 3 1 0 0
D Afro-Caribbean 2 18 5 0 13 0
H East Indian 5 24 11 1 11 1
Total 17 73 36 4 31 2
The characteristics of the five families with familial keloids are shown, including 70 family members overall. Two patients in the study could not be 
contacted to determine presence or absence of keloids. Children <18 yrs are excluded from this table as keloids often appear during adolescence.BMC Dermatology 2009, 9:8 http://www.biomedcentral.com/1471-5945/9/8
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location, treatment (if any), symptomatology, and clinical
progression or regression over time. If an age range was
reported, the mean was calculated, rounded to the nearest
whole number and recorded as onset age. Lesions were
photographed.
We determined the number and location of keloids, with-
out regard to size, in all patients. To simplify tabulation
and to limit the effect of a large number of keloids on the
overall family count for that location, we counted a max-
imum of 5 keloids per location in each subject. We cate-
gorized keloid location according to 13 anatomic areas:
head (other than ears), ears (all aspects of the external
ear), shoulder (axillary fold to inferior deltoid head),
upper arm (inferior deltoid head to antecubital fossa),
lower arm (antecubital fossa to ulnar head), hand (distal
to ulnar head), chest (sternal notch to xiphoid process to
anterior axillary line bilaterally), upper abdomen
Pedigrees of five families with familial keloids Figure 1
Pedigrees of five families with familial keloids. Pedigrees for the five keloid families (D, F, H, K, and R) are shown. Nota-
ble features include the following: vertical transmission without consanguinity, male-to-male transmission, and approximately 
equal numbers of affected and unaffected individuals. Taken together, these findings support dominant or semidominant inher-
itance. Generations available for study are numbered with Roman numerals. Black symbols indicate keloids or keloids plus 
hypertrophic scar; gray symbols indicate hypertrophic scar only. Arrows denote probands. Question marks indicate individuals 
who were not available for study; this includes two individuals in the numbered generations. A dot identifies the three obligate 
carriers, assuming autosomal dominant inheritance.BMC Dermatology 2009, 9:8 http://www.biomedcentral.com/1471-5945/9/8
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(xiphoid process to umbilicus to mid axillary line bilater-
ally), groin (including the lower abdomen and genital
region), back (C2 vertebra to L3 vertebra), buttock (L4
vertebra to gluteal folds), leg (gluteal folds to medial
malleolus), and foot (distal to medial malleolus).
Statistics
Summary statistics include mean and mode. Kruskal-Wal-
lis testing was used to compare the age of onset of keloids
among families; comparison of keloid distribution was by
chi square test (3 × 2 table) or Fisher exact test (2 × 2
table), and comparison of keloid distribution by sex was
by Fisher exact test. Statistical analyses were performed
with Prism and InStat software (GraphPad, San Diego,
CA). A p value < 0.05 was accepted as significant.
Results and Discussion
Probands from four families (D, F, H, and K) contacted
NIH after learning about the study from http://www.Clin
icalTrials.gov. The proband from family R was referred to
investigators by an NIH employee. Of 17 generations rep-
resented in the 5 families, only two generations lacked an
affected individual. This suggested that the mode of inher-
itance might be dominant or semidominant. Further, two
of five pedigrees (H and K) showed evidence of male-to-
male transmission, arguing against X-linked inheritance.
Among individuals with a keloid-affected or status-
unknown parent, the prevalence of keloids was as follows:
family D 38%, family H 45%, family F 62%, family R
67%, and family K 73% (assuming obligate carrier gener-
ation I, Figure 1). These values, averaging 53%, also sug-
gest dominant or semidominant inheritance rather than
recessive inheritance. Taking all families together, adult
males (15/36) and adult females (21/36) were equally
affected by keloids (P = 0.24).
There were three instances in which unaffected individu-
als produced offspring with keloids (D, H, and K). If the
inheritance pattern is dominant or semidominant, the
male in generation III of family H with an affected father,
siblings, and son likely represents an individual with an
allele for keloids without manifesting lesions, an obligate
carrier. Similarly the male in generation I of family D with
an affected sister and two affected daughters and the
female in generation I of family K are also likely obligate
carriers. Assuming autosomal dominant inheritance, the
nonpenetrance rate is 7.9%. An alternative explanation
requires that offspring of these individuals underwent de
novo mutation producing keloids. One, two or five sepa-
rate de novo mutations would be required to explain
affected offspring in family H, D and K respectively.
Keloid characteristics
Keloid severity and morphology differed markedly within
and among families. Lesions ranged from small earlobe
nodules to multiple coalescent fibrous tumors with little
intervening unaffected skin in a particular anatomic
region (Figure 2A and 2B). Some lesions demonstrated
the classic "butterfly" and "dumbbell" morphology, while
others showed hyperpigmented geographic patches con-
sistent with post-inflammatory hyperpigmentation at
sites of reported regressed keloids (Figure 2C and 2D).
Four individuals in three families (F, H, and R Figure 1)
only had hypertrophic scars; none of these individuals
had keloids. All four individuals had parents with keloids
or hypertrophic scars; none had children with keloids. In
addition, seven subjects in 4 families (F, H, K, and R) had
both keloids and hypertrophic scars.
Keloid location also differed within and among families
(Figure 3). The most frequent location for keloids was the
chest (21%). Typical-location keloids, defined as those on
the face, ear, chest, shoulder, back, and upper abdomen
were similarly distributed among all families (p = NS).
Axilla-groin keloids were more common among families
F and K (10/12 individuals) compared to the other fami-
lies (1/14 individuals), p < 0.001 by Fisher exact test (Fig-
ure 3). Of 10 individuals with axilla-groin keloids, two
individuals from family F with multiple axillary keloids
had hidradenitis on physical exam (Figure 2F). One of
these subjects also had multiple groin keloids. No other
subjects examined in any of the five families had hidrad-
enitis. Four of the remaining six individuals in family F
had groin keloids in association with the following
sources of trauma: vasectomy, vulvar shaving, cesarean
section and other surgery. All examined family members
in family K had axilla-groin keloids. Two half-sisters
reported multiple groin keloids following hysterectomy.
Their half-brother reported a single axillary keloid follow-
ing superinfected pseudofolliculitis. Another half-brother
manifested a single groin keloid following surgery in addi-
tion to an axillary keloid of unknown cause. Keloid mor-
phology varied from single nodules to multiple linear
plaques (Figure 2). The increased prevalence of axillary-
groin keloids was not explained by these individuals hav-
ing keloids distributed all over their bodies, as most indi-
viduals had only a few keloids. Extremity keloids, defined
as those on the arm, hand, buttock, leg, and foot, were
more common in family H and K (10/12 individuals),
rare in family F (1/7 individuals) and intermediate in fam-
ilies R and D (3/6 individuals), chi square test for trend p
< 0.002.
The age of keloid onset was obtained by history. The age
reported for first keloid varied from 5 to 52 years,
although most subjects examined (50%) reported onset
of their first keloid between 10 and 19 years (Figure 4A).
Similarly when individuals with multiple keloids were
asked to recall onset age of each lesion, participantsBMC Dermatology 2009, 9:8 http://www.biomedcentral.com/1471-5945/9/8
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reported the largest number of keloids (46%) appearing
between 10 and 19 years (Figure 4B). There were no dif-
ferences among families in age of keloid appearance (p =
0.55). Of 23 subjects under 18 years of age at study end
date, 14 were between 0 and 9 years of age; 9 were
between 10 and 17 years. Of the nine in the latter group,
four had a parent with keloids. Of the 23 subjects <18
years of age none described keloids and five were exam-
ined. None had keloids on physical exam; one, age 17,
had hypertrophic scars (Figure 1, Pedigree R).
Discussion
In the present report, we describe five pedigrees with
familial keloids. Of 17 generations with adult subjects, 15
generations had at least 1 affected individual. This is con-
sistent with autosomal dominant or semidominant inher-
itance given a vertical pattern of transmission, the
presence of male-to-male transmission, and a ratio of
approximately one half affected to non-affected persons
in the absence of consanguinity. All families showed a
similar propensity for keloids to affect the face, ears, and
trunk, which are typical locations for both familial and
sporadic keloids [16,23]. A novel finding is that certain
families also manifested keloids in other locations, with
one family showing an excess of extremity keloids and
two families showing an excess of axilla-groin keloids.
Our findings are generally consistent with other reports
indicating autosomal dominant inheritance for familial
keloids. Bloom et al. and Marneros et al., together
described 45 kindreds [14,15]. Of these, 34 kindreds
included at least 2 generations and all were consistent
with autosomal dominant inheritance. On the other
hand, Omo-Dare et al. indicated that autosomal recessive
inheritance was more likely; data on specific kindreds
were not provided and so the possibility of autosomal
Keloid morphology Figure 2
Keloid morphology. Keloid morphology varied within and across families. Shown is a single keloid on an earlobe and addi-
tional keloids on the cheek (A, family F), multiple keloids with areas of confluence in a severely affected individual (B, family D), 
classic "dumbbell" pattern keloid in the back (C, family H) and keloids on the upper back that have undergone spontaneous 
regression (D, family D). Certain families were more likely to show keloids in atypical locations such as extremities (E, keloids 
on the lateral thigh of an individual from family H) and axilla/groin (F, keloids in the axilla of an individual with hidradenitis from 
family F).
! "
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dominant inheritance with incomplete penetrance cannot
be excluded [17].
Nonpenetrance is common in autosomal dominant disor-
ders. In the five families that are the subject of this report
there were three instances where unaffected parents pro-
duced affected offspring. Assuming autosomal domi-
nance, this suggests a nonpenetrance rate of 7.9%.
Similarly, Marneros et al. reported a nonpenetrance rate of
6.8% after examining fourteen families with autosomal
dominant inheritance [15]. Chen et al. reported a nonpen-
etrance rate of 10% after examining six autosomal domi-
nant families [16].
Keloid phenotype varies markedly [24-26]. The present
study also shows marked variability within and across
Anatomic location of keloids Figure 3
Anatomic location of keloids. The anatomic location of all keloids among the affected individuals of each of the 5 families 
and among the total group of 36 affected individuals is shown.
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families with respect to keloid number, size and severity.
Past authors have ascribed these differences to variable
expressivity [15,16]. Individuals within families could
possess unique genetic modifiers that affect expressivity of
the keloid phenotype.
The present report identified individuals in three families
with hypertrophic scars and seven individuals in four fam-
ilies with both keloids and hypertrophic scars. Hyper-
trophic scars have not been previously reported in
kindreds manifesting familial keloids [15,16,18]. Recent
experiments cross-mating pig of different breeds, one
breed manifesting a fibroproliferative scar phenotype, the
other a normal scar phenotype, produced offspring with
an intermediate healing phenotype [27]. In the present
report, all individuals with hypertrophic scars had a par-
ent with keloids or hypertrophic scars; none had children
with keloids. It is possible that hypertrophic scars repre-
sent a milder manifestation of a keloid genetic diathesis.
Keloid location varied within and across families. While
our sample, analyzed in total, suggests chest and back are
the most common locations for keloids, certain families
seem to show a predilection for relatively atypical areas
such as axilla/groin (two African American families), and
extremities (one South Asian family). Interestingly,
authors have reported that of keloids of the lower limb,
while relatively rare, have the strongest association with
reported family history of keloids from any anatomic
location [25]. Genetic susceptibility may vary by anatomic
site and trends within families could reflect different
mutations in the same gene, locus heterogeneity, or ran-
dom variation. It remains possible that multiple genes
result in keloids and individual families carry different
mutations.
Familial keloids, like sporadic keloids, tended to first
appear during adolescence. In our study, age at onset var-
ied widely (5–52 years) across those sampled, yet 50% of
individuals reported their first lesion between 10 and 19
years of age. Similarly, the largest number of keloids
(46%) seemed to emerge during this interval. Chen
reported similar results in six Han Chinese families with
53% of individuals reporting their first keloid between 11
and 20 years of age [16]. Moustafa et al. reported rapid
enlargement of keloids with severe pruritus and erythema
in a pregnant woman beginning at gestational month
four; symptoms mitigated at delivery [28]. Together the
findings suggest that hormonal milieu may influence
onset and severity of both familial and sporadic keloids.
Our study has important limitations. First, subjects were
identified when they contacted NIH to learn about
research protocols. This approach may select for families
in which at least one family member is severely affected
and more likely to be searching for help. Second, our
study was limited to families with at least three affected
individuals, as we wished to have power for a planned
genome scan. This would be expected to select for families
with autosomal dominant inheritance. Thus, autosomal
recessive inheritance may be more common than our
study and that of others may indicate. Third, although
many patients remembered trauma preceding keloids, we
could not definitively distinguish spontaneous keloids
from those caused by trauma. It is possible that some
patients with a genetic predisposition did not develop kel-
oids, as they had not had sufficient trauma to trigger kel-
oid development. This might explain nonpenetrant cases.
Fourth, subjects who stated they lacked keloids or unusual
scars of any kind were not examined.
Conclusion
We conclude that apparent autosomal dominant inherit-
ance is common among multigenerational families with
keloids, in families of African and South Asian ancestry.
There may be differences between families in the distribu-
Age of keloid onset Figure 4
Age of keloid onset. A) Ages of onset of all keloids in each affected individual are shown. B) Ages of onset of first keloid in 
each affected individual are shown. With both analytic approaches, the modal age of onset was 10–19 years.
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tion of keloids, although more studies of affected families
will be required to confirm these observations.
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